SCHEMBL2902678

SCHEMBL2902678

CSc1ccc(C(C)(CC2CCOCC2)c2ccc(-c3ccccn3)[nH]2)nc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 1/20 0.33
KCNH2 Q12809 1/20 0.33
PCSK9 Q8NBP7 2/20 0.31
MTOR P42345 5/20 0.31
RPTOR Q8N122 4/20 0.31
MLST8 Q9BVC4 4/20 0.31
RICTOR Q6R327 1/20 0.31
MAPKAP1 Q9BPZ7 1/20 0.31
HIF1A Q16665 1/20 0.31
NPC1 O15118 2/20 0.31
TSHR P16473 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
GAA P10253 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899337 0.85 CBFB (0.37) SSTR3KCNH2MTORRPTORMLST8
SCHEMBL2893406 0.70 GRM4 (0.38) NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL2902415 0.67 GPR119 (0.47) MTORRPTORMLST8RICTORMAPKAP1
SCHEMBL2900430 0.66 MTOR (0.34) MTORRPTORMLST8RICTORMAPKAP1
SCHEMBL2901579 0.64 HIF1A (0.33) SSTR3KCNH2HIF1A
SCHEMBL2899552 0.64 RAB9A (0.36) MTORRPTORMLST8RICTORMAPKAP1
SCHEMBL2897151 0.61 GCK (0.39) HIF1A
SCHEMBL2900960 0.61 GCK (0.33) HIF1A
SCHEMBL2899592 0.61 GCK (0.37) MTORCYP1A2CYP2C9CYP2C19PIK3CA
SCHEMBL2901940 0.60 GCK (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318746-B2 Nitrogen-containing five-membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8318746-B2 Nitrogen-containing five-membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8318746-B2 Nitrogen-containing five-membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAS COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-2149550-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-02-03 EP disclosed
EP-2149550-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130446-A1 NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND GCKR, GCK, SLC5A1 SSTR3 1772/4885KCNH2 994/4885PCSK9 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.